Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | TDO2 | P48775 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.34 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.34 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27639689 | 0.79 | TSHR (0.57) | IDO1TDO2TRPA1ALDH1A1MAPK1 | |
| SCHEMBL27655390 | 0.79 | IDO1 (0.41) | IDO1TDO2TRPA1ALDH1A1MAPK1 | |
| SCHEMBL28015399 | 0.79 | IDO1 (0.41) | IDO1TDO2TRPA1ALDH1A1MAPK1 | |
| SCHEMBL5743797 | 0.79 | IDO1 (0.44) | IDO1TDO2TRPA1ALDH1A1MAPK1 | |
| SCHEMBL198178 | 0.79 | TSHR (0.57) | IDO1TDO2TRPA1ALDH1A1MAPK1 | |
| SCHEMBL5740606 | 0.79 | IDO1 (0.44) | IDO1TDO2TRPA1ALDH1A1MAPK1 | |
| SCHEMBL957610 | 0.79 | IDO1 (0.41) | IDO1TDO2TRPA1ALDH1A1MAPK1 | |
| SCHEMBL5743801 | 0.79 | IDO1 (0.44) | IDO1TDO2TRPA1ALDH1A1MAPK1 | |
| SCHEMBL6433380 | 0.78 | IDO1 (0.43) | IDO1TDO2ALDH1A1MAPK1MGLL | |
| Hydrochloric Acid SCHEMBL5741828 | 0.78 | IDO1 (0.47) | IDO1TDO2TRPA1ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040087583-A1 | Amino-thio-acrylonitriles as MEK inhibitors | HOBBS FRANK WORDEN (US) | 2004-05-06 | — | — | US | disclosed |
| US-6703420-B1 | MITOGEN ACTIVATED PROTEIN KINASE (MAPK) INHIBITORS; ANTIINFLAMMATORY, ANTICARCINOGENIC, OR ANTIPROLIFERATIVE AGENTS; RADIOSENSITIZERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-03-09 | — | — | US | disclosed |
| US-20020058699-A1 | Methods for treating seizure disorders by inhibiting MAPK pathway activation | BAYLOR COLLEGE OF MEDICINE | 2002-05-16 | — | — | US | disclosed |
| WO-2002002097-A2 | METHODS FOR TREATING SEIZURE DISORDERS BY INHIBITING MAPK PATHWAY ACTIVATION WITH NITRILES | SWEATT J DAVID (US) | 2002-01-10 | — | — | WO | disclosed |
| EP-1163215-A1 | AMINO-THIO-ACRYLONITRILES AS MEK INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2001-12-19 | — | — | EP | disclosed |
| WO-2000056706-A1 | AMINO-THIO-ACRYLONITRILES AS MEK INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-09-28 | — | — | WO | disclosed |
| EP-0714893-B1 | 2-substituted benzothiazole derivatives useful in the treatment of diabetic complications | GRELAN PHARMACEUTICAL CO (JP) | 1998-10-21 | — | — | EP | disclosed |
| US-5700819-A | ALDOSE REDUCTASE ENZYME INHIBITOR | GRELAN PHARMACEUTICAL CO., LTD. (JP) | 1997-12-23 | — | — | US | disclosed |
| EP-0714893-A1 | 2-substituted benzothiazole derivatives useful in the treatment of diabetic complications | GRELAN PHARMACEUTICAL CO., LTD. (JP) | 1996-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058699-A1 | Methods for treating seizure disorders by inhibiting MAPK pathway activation | MAPKAPK2, MAPK1, MAPK4 | IDO1 4558/4885TDO2 4391/4885TRPA1 1770/4885 |
| US-20040087583-A1 | Amino-thio-acrylonitriles as MEK inhibitors | MAPK1, MAP3K1, CDKN1A | IDO1 461/4885TDO2 2006/4885TRPA1 829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.